Warfarin and bone: implications for rational strategies to selectively antagonize the action of vitamin K in target tissues
Related Experiment Videos
1Department of Biology, University of California, San Diego, La Jolla 92093.
Advances in Experimental Medicine and Biology
|January 1, 1987
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
A serum factor that recalcifies demineralized bone is conserved in bony fish and sharks but is not found in invertebrates.
Calcified tissue international·2006
Protein-Centric Biochemistry Laboratory Experiments from Protein Quantification to Proteomics.
Advances in experimental medicine and biology·2026
Recent Applications of Mass Spectrometry at Clarkson University: An Update.
Advances in experimental medicine and biology·2026
Bottlenecks in Proteomics: An Addendum.
Advances in experimental medicine and biology·2026
Detection of Biomedically Relevant Stilbenes from Wines by Mass Spectrometry: An Update.
Advances in experimental medicine and biology·2026
Application of Ion Mobility Mass Spectrometry in Lipidomics.
Advances in experimental medicine and biology·2026
Glycomics Meets Oncology: The Role of Mass Spectrometry in Cancer Research.
Advances in experimental medicine and biology·2026
Causative factors and outcomes of pyogenic granulomas presenting to a hospital eye clinic.
Clinical & experimental optometry·2026
Meta-Analysis: Potassium-Competitive Acid Blockers Versus Proton Pump Inhibitors for Gastroprotection in Patients Receiving Antiplatelet Therapy.
Alimentary pharmacology & therapeutics·2026
Current practices, challenges, and future directions in subcutaneous oncology monoclonal antibody delivery: a qualitative study.
Expert opinion on drug delivery·2026
Ensuring patient rights, safety, and welfare in "compassionate use" of drugs.
Perspectives in clinical research·2026
Pediatric obesity pharmacotherapy: a practical guide for general pediatricians.
Current opinion in pediatrics·2026
Old Drugs, New Targets: Molecular Docking Insights into Repurposing Proton Pump Inhibitors for the TLR4/MD-2, NLRP3, and C5aR1 Axes in Autoimmune Liver Diseases.
Pharmaceuticals (Basel, Switzerland)·2026